La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Compugen Gestione
Gestione criteri di controllo 3/4
Compugen's Il CEO è Anat Cohen-Dayag, nominato in Jun2009, e ha un mandato di 15.17 anni. la retribuzione annua totale è $ 1.46M, composta da 32.7% di stipendio e 67.3% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.063% delle azioni della società, per un valore di $ 103.26K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.8 anni e 7.1 anni.
Informazioni chiave
Anat Cohen-Dayag
Amministratore delegato
US$1.5m
Compenso totale
| Percentuale dello stipendio del CEO | 32.7% |
| Mandato del CEO | 15.3yrs |
| Proprietà del CEO | 0.06% |
| Durata media del management | 4.8yrs |
| Durata media del Consiglio di amministrazione | 7.2yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Investors Aren't Buying Compugen Ltd.'s (NASDAQ:CGEN) Revenues
Aug 22
Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report
May 22Why Investors Shouldn't Be Surprised By Compugen Ltd.'s (NASDAQ:CGEN) 25% Share Price Plunge
May 01Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?
Apr 05Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Mar 08Compugen (NASDAQ:CGEN) Is In A Good Position To Deliver On Growth Plans
Feb 17Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?
Oct 10Is Compugen (NASDAQ:CGEN) In A Good Position To Invest In Growth?
Jun 22Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation
Mar 04Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Sep 21Compugen appoints Alberto Sessa as CFO
Sep 12Compugen gets Japanese patent for COM701, anti-PVRIG antibodies
Aug 24Compugen Q2 2022 Earnings Preview
Aug 03Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Jun 23Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Mar 02Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation
Nov 04Shareholders Will Probably Not Have Any Issues With Compugen Ltd.'s (NASDAQ:CGEN) CEO Compensation
Aug 27Companies Like Compugen (NASDAQ:CGEN) Can Afford To Invest In Growth
Jun 28Compugen gains on takeover speculation after iTeos Therapeutics deal
Jun 14Compugen reports updated COM701 data from Phase 1 study at ASCO21
Jun 08Compugen's COM902 demonstrates potential benefit in cancer
Apr 27Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation
Mar 15Are Institutions Heavily Invested In Compugen Ltd.'s (NASDAQ:CGEN) Shares?
Feb 08
A Look At The Fair Value Of Compugen Ltd. (NASDAQ:CGEN)
Jan 04Compugen earns $2M milestone under antibody development deal with AstraZeneca
Dec 23Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation
Nov 30Compugen Ltd. 2020 Q3 - Results - Earnings Call Presentation
Nov 08Compugen: Speculative Play For Immuno-Oncology Exposure
Nov 07Compugen Q3 Earnings Preview
Nov 04Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$10m |
| Mar 31 2024 | n/a | n/a | -US$17m |
| Dec 31 2023 | US$1m | US$479k | -US$19m |
| Sep 30 2023 | n/a | n/a | -US$32m |
| Jun 30 2023 | n/a | n/a | -US$33m |
| Mar 31 2023 | n/a | n/a | -US$33m |
| Dec 31 2022 | US$1m | US$479k | -US$34m |
| Sep 30 2022 | n/a | n/a | -US$39m |
| Jun 30 2022 | n/a | n/a | -US$34m |
| Mar 31 2022 | n/a | n/a | -US$34m |
| Dec 31 2021 | US$1m | US$498k | -US$34m |
| Sep 30 2021 | n/a | n/a | -US$34m |
| Jun 30 2021 | n/a | n/a | -US$36m |
| Mar 31 2021 | n/a | n/a | -US$32m |
| Dec 31 2020 | US$1m | US$453k | -US$30m |
| Sep 30 2020 | n/a | n/a | -US$28m |
| Jun 30 2020 | n/a | n/a | -US$26m |
| Mar 31 2020 | n/a | n/a | -US$26m |
| Dec 31 2019 | US$941k | US$395k | -US$27m |
| Sep 30 2019 | n/a | n/a | -US$30m |
| Jun 30 2019 | n/a | n/a | -US$27m |
| Mar 31 2019 | n/a | n/a | -US$31m |
| Dec 31 2018 | US$854k | US$391k | -US$23m |
| Sep 30 2018 | n/a | n/a | -US$23m |
| Jun 30 2018 | n/a | n/a | -US$29m |
| Mar 31 2018 | n/a | n/a | -US$28m |
| Dec 31 2017 | US$740k | US$392k | -US$37m |
Compensazione vs Mercato: La retribuzione totale di Anat ($USD 1.46M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 1.54M ).
Compensazione vs guadagni: La retribuzione di Anat è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
Anat Cohen-Dayag (57 yo)
15.3yrs
Mandato
US$1,464,448
Compensazione
Dr. Anat Cohen-Dayag, Ph D., served as an Independent Director at Gamida Cell Ltd since January 28, 2022 until March 2023. She serves as Director at has been Chief Executive Officer and President at Compug...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO, President & Director | 15.3yrs | US$1.46m | 0.063% $ 101.3k | |
| Chief Scientific Officer | 4.5yrs | US$540.64k | Nessun dato | |
| Senior Vice President of Technology Innovation | 6.7yrs | US$532.26k | Nessun dato | |
| Vice President of Preclinical Development | 3.4yrs | US$570.40k | Nessun dato | |
| Chief Financial Officer | less than a year | Nessun dato | Nessun dato | |
| Head of Investor Relations & Corporate Communications | no data | Nessun dato | Nessun dato | |
| General Counsel & Corporate Secretary | 5.7yrs | Nessun dato | Nessun dato | |
| Vice President of Human Resources | 17.7yrs | Nessun dato | Nessun dato | |
| Senior VP & Senior Advisor of Data and Informatics Solutions | 4.8yrs | Nessun dato | Nessun dato | |
| Vice President Research and Discovery | no data | Nessun dato | Nessun dato | |
| Chief Medical Officer | less than a year | Nessun dato | Nessun dato |
4.8yrs
Durata media
53yo
Età media
Gestione esperta: Il team dirigenziale di CGEN è considerato esperto (durata media dell'incarico 4.8 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO, President & Director | 10.6yrs | US$1.46m | 0.063% $ 101.3k | |
| Member of Scientific Advisory Board | 4yrs | Nessun dato | Nessun dato | |
| Independent Director | 6.3yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 11.1yrs | Nessun dato | Nessun dato | |
| Independent Director | 6.3yrs | Nessun dato | Nessun dato | |
| Independent Chairman of the Board | 6.9yrs | Nessun dato | Nessun dato | |
| Independent Director | 6.3yrs | Nessun dato | Nessun dato | |
| Chairman of Scientific Advisory Board | 10.7yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 11.1yrs | Nessun dato | Nessun dato | |
| Independent Director | 5.2yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 11.1yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 7.5yrs | Nessun dato | Nessun dato |
7.2yrs
Durata media
58yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di CGEN sono considerati esperti (durata media dell'incarico 7.1 anni).